MedPage Today |
UPDATE 1-FDA panel backs approval of GSK asthma drug in adults
Reuters If approved, the drug would be marketed under the trade name Nucala and be the first new biologic treatment for severe asthma in more than a decade. Asthma affects more than 22 million people in the United States. Severe asthma accounts for 5 to 10 … UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in … Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers FDA committee recommends approval of Nucala for adults with severe asthma |
View full post on asthma – Google News